Zai Lab
ZLAB
38 hedge funds and large institutions have $286M invested in Zai Lab in 2018 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 15 increasing their positions, 12 reducing their positions, and 3 closing their positions.
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
25% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 12
24% more capital invested
Capital invested by funds: $231M → $286M (+$55M)
9% more funds holding
Funds holding: 35 → 38 (+3)
2.38% more ownership
Funds ownership: 21.99% → 24.37% (+2.4%)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $377K
Top Buyers
| 1 |
O
OrbiMed
New York
|
+$20.5M |
| 2 |
Millennium Management
New York
|
+$5.95M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.07M |
| 4 |
SCM
Segantii Capital Management
Hong Kong
|
+$3.22M |
| 5 |
BlackRock
New York
|
+$919K |
Top Sellers
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$1.14M |
| 2 |
MWNA
Marshall Wace North America
New York
|
-$968K |
| 3 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$905K |
| 4 |
SG Americas Securities
New York
|
-$823K |
| 5 |
Goldman Sachs
New York
|
-$442K |
ZLAB Hedge Fund Activity: Q2 2018 in Review
38 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Zai Lab (ZLAB) for Q2 2018, worth a combined $286M — up 24% from $231M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ZLAB positions and 3 closed out — a net gain of 4 holders — while 15 added to existing stakes and 12 trimmed.
The largest buyer was OrbiMed, adding an estimated $20.5M. The largest seller was Vivo Capital, cutting an estimated $1.14M.
- 38 institutional investors held Zai Lab (ZLAB) as of Q2 2018, up from 35 in Q1 2018.
- Funds reported $286M of Zai Lab stock for Q2 2018, up 24% quarter-over-quarter.
- 7 funds opened new Zai Lab positions in Q2 2018 and 3 closed out, a net change of +4 holders.
- The largest Zai Lab buyer in Q2 2018 was OrbiMed, an estimated $20.5M added.
- The largest Zai Lab seller in Q2 2018 was Vivo Capital, an estimated $1.14M sold.
Based on aggregated 13F filings for Q2 2018.